In addition, other researchers have also observed that, in the treatment of NSCLC, cervical cancer, breast cancer, and colorectal cancer, anti-PD-L1 treatment may trigger the accumulation of immunosuppressive M2 macrophages characterized by a CD163+PD-L1+ phenotype at the tumor site and the accumulation of M2 macrophages may worsen the prognoses of patients treated with ICIs [85,86,87,88]. This evidence concerns the gene CD274 and neoplasm.